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Abstract
Background: To determine whether deep dry needling (DDN) of trigger points (TPs) in the lateral pterygoid mus-
cle (LPM) would significantly reduce pain and improve function, compared with methocarbamol/paracetamol 
medication.
Material and Methods: Forty-eight patients with chronic myofascial pain located in the LPM were selected and 
randomly assigned to one of two groups (DDN test group, n=24; drug-treated control group, n=24). The test group 
received three applications of needling of the LPM once per week for three weeks, while control group patients 
were given two tablets of a methocarbamol/paracetamol combination every six hours for three weeks. Assess-
ments were carried out pre-treatment, 2 and 8 weeks after finishing the treatment.
Results: A statistically significant difference (p<0.05) was detected for both groups with respect to pain reduction 
at rest and with mastication, but the DDN test group had significantly better levels of pain reduction. Moreover, 
statistically significant differences (p<0.05) up to day 70 in the test group were seen with respect to maximum 
mouth opening, laterality and protrusion movements compared with pre-treatment values. Pain reduction in the 
test group was greater as a function of pain intensity at baseline. The evaluation of efficacy as assessed both by 
patients/investigators was better for the test group. 41% of the patients receiving the combination drug treatment 
described unpleasant side effects (mostly drowsiness).
Conclusions: DDN of TPs in the LPM showed better efficacy in reducing pain and improving maximum mouth 
opening, laterality, and protrusion movements compared with methocarbamol/paracetamol treatment. No adverse 
events were observed with respect to DDN.
Key words: Myofascial pain syndrome, myofascial trigger points, deep dry needling, lateral pterygoid muscle, 
randomized controlled trial, temporomandibular disorders.
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Introduction
Myofascial pain syndrome (MPS) is a complex disorder 
of the musculoskeletal system with multifactorial in-
volvement and diverse clinical presentations in several 
areas of the body, one of them being in the orofacial re-
gion with involvement of the temporo-mandibular joint 
(TMJ) and masticatory muscles (1). MPS must be sus-
pected in patients with pain in the masticatory muscles, 
along with the existence of painful trigger points (TPs) 
on palpation, and limitation of interincisal opening (2). 
One of the masticatory muscles most frequently affect-
ed is the lateral pterygoid muscle (LPM) (3), and deep 
dry needling (DDN) is one of the techniques used for 
treating. Its purpose is to inactivate the TPs (4), this be-
ing an essential outcome for the effective management 
of this pathology. Literature reports attest to the safety, 
efficacy and low cost of this treatment approach (5-12). 
The objective of the present study was to investigate 
whether DDN of the LPM could reduce pain and en-
hance mandibular mobility compared with adminis-
tration of a methocarbamol/paracetamol combination 
treatment. Secondary objectives were to assess the level 
of improvement in the general state of the TMJ, as well 
as to assess patient tolerance to the treatments followed, 
and side effects reported.
Material and Methods
- Subjects
An open, randomized, single center clinical trial was 
carried out at the Outpatient Clinic of the Department 
of Oral and Maxillofacial Surgery at the Virgen del Ro-
cio University Hospital, Seville (Spain), between May 
and October 2013. Male and female patients between 
18 and 65 years of age with temporo-mandibular myo-
fascial pain located in the LPM were enrolled follow-
ing confirmation of MPS according to clinical signs of 
Simons (4,13) and imaging results, panoramic radiogra-
phy and magnetic resonance imaging (MRI), to rule out 
the presence of other conditions. We included patients 
with temporo-mandibular myofascial pain of more than 
six months’ duration only or with moderate limitation 
of mandibular movement (interincisal opening limited 
to <40 mm and passive stretching required to force the 
opening by ≥ 5 mm, according to Group I criteria of 
the International RDC-TMD Consortium (14), with the 
presence of TPs in the LPM. The following inclusion 
diagnostic criteria were assessed: a) strong pain in the 
anterior part of the lower belly of the LPM on palpa-
tion; b) deep-seated pain in the TMJ and/or region of the 
maxillary sinus (referred pain); and c) significant motor 
dysfunction (limited jaw opening, painful protrusion of 
the chin against resistance, mandibular lateralization 
to the opposite side upon opening). Subjects were ex-
cluded if they presented with one or more of the follow-
ing conditions: TMJ internal derangements with ante-
rior disk displacement without reduction, degenerative 
joint disease, history of jaw trauma, vascular diseases, 
migraine and tension headaches, and history of infec-
tious-inflammatory conditions of odontogenic origin. If 
another TP can be detected in any of the other elevator 
muscles, these areas were inactivated before DDN of TP 
in the LPM, so that 8 patients of our study with TPs 
also in masseter muscle received, in addition to treat-
ment with DDN, an adjuvant treatment with deep tissue 
massage and manual stretching of the masseter muscle 
in order to prepare the treatment area (LPM) by muscle 
relaxation of adjacent structures.
The Committee for Research and Clinical Ethics of the 
Hospital approved the study (2013PI/119). Declaration 
of Helsinki guidelines was followed. Before inclusion, 
all patients signed an informed consent form. 
- Study Design
Patients were assigned randomly to one of two groups 
(Epidat 4.0). The DDN group received needling of the 
LPM once per week for 3 weeks. Clinical evaluations 
were carried out at the basal day (day 0), and on days 28 
and 70 after the commencement of treatment. Data were 
collected at each visit by a same observer. For the DDN 
therapy, sterile stainless steel needles (length 40 mm/ ca-
liber 0.25 mm, with a cylindrical plastic guide; Agu-punt 
®) were used (Fig. 1). The preauricular area was swabbed 
with 90° alcohol, and the LPM manually located in-
tra and extra-orally, unilaterally (Fig. 2). Intramuscular 
needling was then carried out. This was performed via 
a deep puncture into myofascial pain TPs without the in-
troduction of any substance (dry needling) (Fig. 3) (4,15). 
The aim was to provoke a jump reaction or local twitch 
response (LTR) in all cases when the needle was inserted 
into a TP (3,15,16). The procedure was followed by com-
pressive haemostasis for one minute.
The control group was given a methocarbamol (380 mg) 
and paracetamol (300 mg) combination drug therapy, 
at a dose of two tablets every six hours for three weeks. 
For the control group, clinical evaluations were con-
ducted at the basal day (day 0), and on days 28 and 70 
following commencement of the study. Data were col-
lected at each visit by a same observer.
- Measures
The main parameters to assess the effectiveness of the 
treatment were: 1) pain at rest and upon mastication us-
ing the visual analogue scale (VAS 10 cm), and 2) range 
of mandibular movements associated with opening of 
the mouth, lateral movements and protrusion measured 
with a Therabite® ruler. Signs that were evaluated as in-
dicators of the effectiveness of the DDN were: signifi-
cant reduction in myofascial pain at rest and with mas-
tication, recovery of normal ranges of mouth opening, 
lateral and protrusive movements, and improved per-
formance of the TMJ. In addition, TMJ affectation was 
assessed using a questionnaire consisting of a 100-point 
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Fig. 1. Range of mandibular movements was measured with a Therabite® ruler. For the DDN, sterile 
stainless steel needles (length 40 mm and caliber 0.25 mm, with a cylindrical plastic guide; Agu-punt 
®) were used.
Fig. 2. Anatomic location of the lateral pterygoid muscle for nee-
dling.
Fig. 3. The needle was inserted taking into account the relationship 
between the muscle and TPs with the surrounding anatomical struc-
tures. The presence of a local twitch response during DDN is impor-
tant given its proven relationship with the desired therapeutic effect.
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scale (0 worst state, 100 optimum state) based on pain 
(maximum 40 points), function (45 points) and masti-
cation (15 points). Secondary efficacy outcomes were 
overall efficiency ratings assessed by the patient and 
the authors using a 5-point scale ranging from worst-0 
to optimum-4. Tolerability to the treatment was evalu-
ated by the patient and the authors using a 5-point scale 
(0-very bad, 1-bad, 2-acceptable, 3-good, 4-excellent). 
The type and frequency of adverse events were record-
ed at each visit. 
- Statistical Analysis
Data were analyzed with statistical software (IBM 
SPSS Statistics 19.0). Longitudinal data were analyzed 
first with an overall statistical test (Friedman test).  Ab-
solute and relative frequencies were used in the case of 
qualitative variables. The Shapiro-Wilk test  (n<50) for 
normality was used for quantitative variables, which 
were expressed as average and standard deviation (SD) 
or as the fiftieth percentile (P50; median), or P25-P75 
(interquartile range). Non-normally distributed data 
were analyzed with non-parametric tests. Pre- and post-
intervention comparisons of the variables in each group 
were performed using the Friedman test and the Wil-
coxon signed ranks test (with Bonferroni correction) to 
analyze intra-group variations between day 0 and day 
28 and between day 0 and day 70. Comparisons be-
tween the study groups were carried out with the Mann-
Whitney U-test for each time point. Values of p<0.05 
were considered to indicate statistical significance.
Results
Forty-eight patients were selected and randomized to 
the study (DDN test group, n=24; drug-treated control 
group, n=24). Both groups had identical male-to-female 
ratios (5 males: 19 females), and similar age distribu-
tions (mean 34.3 SD ± 13.8 years in the DDN group vs. 
35.5 ± 11.2 in the control group). In the DDN group, the 
right and left TMJ were affected in 12 cases each; in the 
control group, the right TMJ was affected in 16 of the 24 
patients and the left TMJ in the remainder. Radiographic 
findings showed no alteration in the morphology of the 
articular surfaces. MRI studies revealed no significant 
changes. All patients from DDN group completed the 
trial, whereas in the drug group 8 patients terminated 
the study prematurely in the review phase (not receiving 
medication at that time).
Data from the tables are the median of the differences 
between the different days. From day 0 to day 70, the 
median pain score at rest in the DDN group decreased 
a rate of 68%, and 63% for the control group. For each 
group, the reduction in pain at rest was statistically sig-
nificant on days 28 and 70 with respect to day 0, while 
the reduction of pain at rest produced in both groups 
was significantly better in the DDN group compared 
with the control group on day 28 (p=0.005) and on day 
70 (p=0.016) (Table 1).
From the beginning of the study to day 70, mastication-
associated pain decreased, in DDN and control groups, 
a rate of 69%, and 72% respectively. The pain reduction 
with mastication was statistically significant at day 28 
for both groups, and on day 70 for the DDN group alone. 
A comparison of the reduction in pain produced in both 
groups highlighted a statistically significant greater re-
duction of pain in the DDN group compared with the 
control group on day 28 (p<0.001) and day 70 (p=0.011) 
(Table 1).
 PAIN AT REST PAIN ON MASTICATION 
DDN Group 
(n=24) 
Control Group 
(n=24) 
DDN Group 
(n=24) 
Control Group 
(n=24) 
 Me [P25-P75] Me [P25-P75] P Me [P25-P75] Me [P25-P75] P 
Day 0 
5.65 [4.65-7.17] 
(n=24) 
5.10 [2.92-6.80] 
(n=24) 
0.164 † 
6.75 [5.77-8.30] 
(n=24) 
6.15 [1.15-8.17] 
(n=24) 
0.063 † 
Day 28 
1.92 [1.02-2.20] 
(n=24) 
2.10 [0.32-5.72] 
(n=24) 
0.293 † 
2.15 [1.52-4.02] 
(n=24) 
 2.85 [0.30-6.90] 
(n=24) 
0.563 † 
ǻ 0-28 4.10 [2.00-5.20] 1.50 [0.30-2.38] 0.005* ‡ 4.50 [2.12-5.75 1.40 [0.10-2.15] 0.000* ‡ 
Day 70 
1.80 [0.30-3.40] 
(n=23) 
1.90 [0.30-3.92] 
(n=16)  
0.886 † 
2.10 [0.50-5.00] 
(n=23) 
1.75 [0.20-4.27] 
(n=16) 
0.587 † 
ǻ 0-70 3.70 [1.90-6.00] 1.80 [1.12-2.37] 0.016* § 4.40 [1.60-6.60] 1.70 [0.02-3.55] 0.011* § 
Table 1.  Pain at rest and on mastication.
Pain at rest and on mastication measured on a 10-cm VAS (Visual Analogue Scale). Patients were treated with 3 applications of DDN or 
with an oral methocarbamol-paracetamol combination therapy. Data from the tables are the median of the differences between the different 
days.
Abbreviation: Me, Median. P25-P75, 25th–75th Percentile.
* Results considered significant (p<0 .05).
† Mann-Whitney U test for comparative analysis at each visit for each independent group. 
‡ Mann-Whitney U test for comparative analysis of reduction of median VAS on day 28 (from day 0) for the two groups.
§ Mann-Whitney U test for comparative analysis of reduction of median VAS on day 70 (from day 0) for the two groups.
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The DDN group showed improvements in the maxi-
mum mouth opening, left side, right side and protru-
sion movements from day 0 to day 70; these increased, 
respectively, a rate of 2%, 38%, 29% and 40%. Patients 
in the control group showed improved median move-
ments involving opening of the mouth and displacement 
to the left side on day 70 with respect to day 0, increas-
ing, respectively, a rate of 13.75% and 13%. However, in 
the control group, the range of right side lateral move-
ment showed no variation on day 70 with respect to 
day 0, and the protrusion distance decreased 20% on 
day 70. Improvement in the movements of maximal 
mouth opening, left side, right side lateral movements 
and protrusion was statistically significant only for the 
DDN group on days 28 and 70. Mandibular protrusion 
in the DDN group data was significantly better than 
in the control group on day 28 (p=0.031) and day 70 
(p=0,001). A comparison of the change in each of the 
mandibular movements seen in each group on days 28 
and 70 showed that the movements of left side, right side 
and protrusion in the DDN group were statistically sig-
nificantly improved compared with the control group, 
but no significant improvement in maximum opening 
was seen (Tables 2,3,4).
 JAW OPENING 
DDN Group 
(n=24) 
Control Group 
(n=24) 
 Me [P25-P75] Me [P25-P75] P 
Day 0 42.00 [35.00-46.75]  (n=24) 
40.00 [36.50-48.75]  
(n=24) 0.812 † 
Day 28 43.50 [40.00-49.75] (n=24) 
42.00 [34.75-49.00] 
(n=24) 0.549 † 
ǻ 0-28 3.00 [0.50-6.00] 2.00 [-1.75-5.00] 0.218 ‡ 
Day 70 43.00 [40.00-46.00] (n=23) 
45.50 [39.75-49.75] 
(n=16)  0.519  † 
ǻ 0-70 5.00 [-1.00-6.00] 2.00 [-1.00-9.00] 0.966 § 
Table 2.  Jaw opening.
Range of jaw opening movement measured using a Therabite® System ruler. Patients were 
treated with three applications of DDN or with an oral methocarbamol/paracetamol combi-
nation therapy. Data from the table are the median of the differences between the different 
days.
Abbreviation: Me, Median. P25-P75, 25th–75th Percentile.
* Results considered significant (p<0.05).
† Mann-Whitney U test for comparative analysis at each visit for each independent group. 
‡ Mann-Whitney U test for comparative analysis of the median increase in jaw opening 
measured with a Therabite® System ruler on day 28 (from day 0) for the two groups.
§ Mann-Whitney U test for comparative analysis of the median increase in jaw opening 
measured with a Therabite® System ruler on day 70 (from day 0) for the two groups.
 LEFT LATERAL MOVEMENT RIGHT LATERAL MOVEMENT 
DDN Group 
(n=24) 
Control Group 
(n=24) 
DDN Group 
(n=24) 
Control Group 
(n=24) 
 Me [P25-P75] Me [P25-P75] P Me [P25-P75] Me [P25-P75] P 
Day 0 
6.50 [5.00-9.00]  
(n=24) 
8.00 [6.00-10.00]  
(n=24) 
0.142 † 
7.00 [5.00-9.00]  
(n=24) 
9.00 [5.25-10.00] 
(n=24) 
0.181† 
Day 28 
9.50 [8.00-10.00] 
(n=24) 
9.00 [7.00-10.00]  
(n=24) 
0.078 † 
9.50 [8.00-10.00] 
(n=24) 
 9.00 [6.50-10.00] 
(n=24) 
0.451† 
ǻ 0-28 1.00 [0.00-3.00] 0.00 [-1.00-1.00] 0.005* ‡ 1.00 [0.00-3.00] 0.00 [-1.00-1.00] 0.005* ‡ 
Day 70 
9.00 [8.00-10.00] 
(n=23) 
9.00 [8.00-9.00] 
(n=16)  
0.056 † 
9.00 [7.00-10.00] 
(n=23) 
9.00 [8.00-9.00] 
(n=16) 
0.119 † 
ǻ 0-70 2.00 [1.00-4.00] -0.50 [-1.75-1.75] 0.006* § 2.00 [1.00-3.00] 1.00 [-2.00-0.75] 0.001* § 
Range of left/ right lateral mandibular movement measured using a Therabite® System ruler. Patients were treated with three ap-
plications of DDN or with an oral methocarbamol/ paracetamol combination therapy. Data from the tables are the median of the 
differences between the different days.
Abbreviation: Me, Median. P25-P75, 25th–75th Percentile.
* Results considered significant (p<0.05).
† Mann-Whitney U test for comparative analysis at each visit for each independent group. 
‡ Mann-Whitney U test for comparative analysis of the median increase in left/ right lateral movement measured with a Therabite® 
System ruler on day 28 (from day 0) for the two groups.
§ Mann-Whitney U test for comparative analysis of the median increase in left/ right lateral movement measured with a Therabite® 
System ruler on day 70 (from day 0) for the two groups.
Table 3. Left and right lateral movements.
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An evaluation of the functionality of the TMJ showed 
that median scores in the DDN group improved almost 
a rate of 56%, from the beginning of the study to day 70. 
In the control group, there was an improvement in the 
median score with an increase of 35%. The improvement 
in the TMJ functionality was statistically significant on 
days 28 and 70 of the study for both groups. The change 
in scores that took place from days 0-28 and 0-70 of 
the study showed a statistically significant improvement 
for the DDN group compared with the control group 
(p=0.027) with regards to the day 28 score, but not the 
day 70 score. We also observed a statistically significant 
difference (p=0.030) between the initial scores for both 
groups (day 0), but this was not relevant from a clinical 
point of view because patients were randomly assigned 
to groups.
Patients in the DDN and control groups considered the 
outcome of their treatment to be optimal in 42% and 
13% of cases, respectively, while for the authors these 
values were 50% and 8% for the respective groups. Tol-
erance to the treatment was evaluated by patients as ex-
cellent in 25% and 4% for the DDN and control groups, 
respectively. No patients in the DDN group exhibited 
side effects on any of the days of the study, while 10 
patients (41%) in the control group reported side effects 
related to drug therapy (consisting mainly of drowsi-
ness). 
Discussion
Clinical guidelines related to the treatment of TMD 
recommend the management of myofascial pain from a 
multidisciplinary approach. However, within available 
treatments for chronic muscle pain, there is a paucity of 
studies about the effectiveness of TP needling in mas-
ticatory muscles, thus giving rise to our objective of 
studying the DDN of myofascial TPs in the LPM. The 
mechanism of inactivation of a TP by needling is un-
known, although we consider that the presence of a LTR 
during DDN is important given its proven relationship 
with the desired therapeutic effect (3,4,13,15-21).  
Since stretching techniques and massage are difficult 
and complicated by the limited spatial access to the 
LPM, needling of TPs may be necessary (3,4,9). The 
critical importance of this muscle as origin of tempo-
romandibular myofascial pain makes acquisition of the 
skills necessary for performing TP needling a worth-
while exercise. The external approach (extraoral DDN) 
permits needling of the central TPs in the muscle bellies 
of the two divisions of the muscle and of the insertional 
TPs of the posterior myotendinous junctions of both 
divisions (3,4). Determining the correct location of the 
muscle mass is essential for the technique we use, so in-
terfering factors represented by the nearby bony struc-
tures (zygomatic arch, coronoid process, condyle and 
sigmoid notch of the mandible) must be circumvented. 
There seems to be no need to carry out the electromyo-
graphic control (22), given the TPs can be detected by 
following the diagnostic criteria already described and 
by obtaining a LTR during needling. 
The objective of the present study was to evaluate the 
efficacy of three applications of such needling of the 
LPM on a once per week basis for three weeks. In 
 PROTRUSION MOVEMENT 
DDN Group 
(n=24) 
Control Group 
(n=24) 
 Me [P25-P75] Me [P25-P75] P 
Day 0 
5.00 [3.00-5.00]  
(n=24) 
5.00 [4.25-5.00]  
(n=24) 
0.181 † 
Day 28 
5.00 [5.00-7.00] 
(n=24) 
5.00 [5.00-5.00]  
(n=24) 
0.031* † 
ǻ 0-28 1.50 [0.00-3.00] 0.00 [0.00-1.00] 0.016* ‡ 
Day 70 
7.00 [5.00-8.00] 
(n=23) 
4.00 [4.00-5.00]  
(n=16)  
0.000* † 
ǻ 0-70 2.00 [1.00-3.00] 0.00 [-1.00-0.75] 0.000* § 
Table 4.  Protrusion movement.
Range of protrusion movement measured using a Therabite® System ruler. Patients were 
treated with three applications of DDN or with an oral methocarbamol/paracetamol combi-
nation therapy. Data from the table are the median of the differences between the different 
days.
Abbreviation: Me, Median. P25-P75, 25th–75th Percentile.
* Results considered significant (p<0.05).
† Mann-Whitney U test for comparative analysis at each visit for each independent group. 
‡ Mann-Whitney U test for comparative analysis of the median increase in protrusion move-
ment measured with a Therabite® System ruler on day 28 (from day 0) for the two groups.
§ Mann-Whitney U test for comparative analysis of the median increase in protrusion move-
ment measured with a Therabite® System ruler on day 70 (from day 0) for the two groups.
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this way, a comparison was made of pain intensity at 
rest and upon mastication, as well as measurements 
of ranges of maximum mouth opening, laterality, and 
protrusion movements. The results showed statistically 
significant differences in favor of DDN compared with 
respect to an oral methocarbamol/paracetamol combi-
nation therapy. Neither treatment was superior to the 
other concerning the limitation of mandibular opening. 
In the DDN-treated patients, parameters were signifi-
cantly improved in both follow-up visits (days 28 and 
70) compared to day 0. This was not the case for the 
control group, where only pain on day 28 was statis-
tically significantly improved. When we evaluated the 
functionality of the TMJ, with the 100-point test, the 
DDN treatment approach was clearly superior. Simi-
larly, the overall assessment by patients and authors of 
the effectiveness of the treatment, and the evaluation 
of treatment tolerance by patients, was better with the 
three applications of DDN than with methocarbamol/
paracetamol combination treatment. Pain reduction in 
the DDN-treated group was greater the higher was pain 
intensity at baseline (day 0). The global evaluation of ef-
ficacy as assessed both by patients and authors was bet-
ter for the DDN test group. No adverse reactions were 
detected with DDN, whereas up to 41% of the patients 
receiving the combination drug treatment described un-
pleasant side effects (drowsiness).
This study has some limitations. First, treatment ap-
praisal was limited only to the effects seen in the short- 
and mid-term (eight weeks following completion of 
DDN of TPs in the LPM). A study with a larger size 
sample and a longer follow-up period is required to de-
termine the long-term benefits of DDN of TPs in this 
muscle. A second limitation is that the study was not 
a real doubled-blind and included an active treatment 
comparison group with methocarbamol/ paracetamol, 
as a control group. A third limitation is that the con-
trol group had a significant number of withdrawal study 
subjects (8 patients), with the main reason for dropping 
out being due to personal difficulties associated with 
patients keeping their scheduled appointments.
To conclude, DDN of TPs in the LPM showed better ef-
ficacy and safety in reducing pain and improving maxi-
mum mouth opening, laterality, and protrusion move-
ments in patients with chronic myofascial pain located 
on that muscle, compared with an oral methocarbamol/
paracetamol combination therapy. The improvement 
persisted for 8 weeks following completion of the treat-
ment, and was proportional to the intensity of the pain 
at the beginning of the study. Our study also suggested 
that patients with a poorer functional status prior to 
treatment obtained the best final outcomes. No serious 
adverse events were observed with respect to the dry 
needling technique.
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